Moroctocog alfa

Clinical data
Trade names	ReFacto
AHFS/Drugs.com	UK Drug Information
Legal status	℞ (Prescription only)
Identifiers
ATC code	B02BD02
ChemSpider	none
Chemical data
Molar mass	170 kDa

Moroctocog alfa (trade name ReFacto) is a recombinant antihemophilic factor genetically engineered from Chinese hamster ovary (CHO) cell line. Chemically it is a glycoprotein.^[1] It is manufactured by Genetics Institute, Inc. and used to control and prevent hemorrhagic bleeding and prophylaxis associated with surgery or to reduce the number of spontaneous bleeding episodes in patients with hemophilia A. It is partially a recombinant coagulation factor VIII since it has an amino acid sequence which compares to the 90 + 80 kDa form of factor VIII (BDDrFVIII).^[2] It also has posttranslational modifications which are similar to those of the plasma-derived molecule. It can not prevent hemorrhagic bleeding associated with von Willebrand's disease since it is not a von Willebrand factor.

References

Antihemorrhagics (B02)

Antihemorrhagics
(coagulation)

Systemic

Vitamin K	Phytomenadione (K₁) Menadione (K₃)

Coagulation factors	intrinsic: IX/Nonacog alfa VIII/Moroctocog alfa/Turoctocog alfa extrinsic: VII/Eptacog alfa common: X II/Thrombin I/Fibrinogen combinations: Prothrombin complex concentrate (II, VII, IX, X, protein C and S)

Other systemic	Etamsylate Carbazochrome Batroxobin thrombopoietin receptor agonist (Romiplostim Eltrombopag)

Local

Antifibrinolytics

amino acids (Aminocaproic acid
Tranexamic acid
Aminomethylbenzoic acid)
serpins (Aprotinin
Alfa1 antitrypsin
C1-inhibitor
Camostat)

This article is issued from Wikipedia - version of the Thursday, November 19, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.